CLS Holdings Partners with SOMA to Launch Innovative Solventless Cannabis Vape
LAS VEGAS, NV / ACCESSWIRE / March 5, 2024 / CLS Holdings USA, Inc. (OTCQB:CLSH)(CSE:CLSH), the ''Company'' or ''CLS'', a...
Year: 2024
New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure
Salix Pharmaceuticals Releases Findings from First Colonoscopy Awareness SurveyLAVAL, QC / ACCESSWIRE / March 5, 2024 / Bausch Health Companies...
FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
TORONTO, ON / ACCESSWIRE / March 5, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
Bone Health Technologies Secures $5 Million in Funding to Transform Osteopenia Care
BHT closes oversubscribed financing round, adds new investors to revolutionize low bone density treatmentsREDWOOD CITY, CA / ACCESSWIRE / March...
Zomedica to Present at the Sidoti Small Cap Conference March 14, 2024
ANN ARBOR, MI / ACCESSWIRE / March 5, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary...
AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV
• Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans•...
Noom Earns Highest CDC Recognition for Diabetes Prevention Program
The CDC Full Plus Recognition sets a new standard for digital health solutions providing metabolic health, chronic disease prevention, and...
Accelus President & CEO Kevin McGann to Present at LSI USA ’24 Conference
Accelus President & Chief Executive Officer Kevin McGann Kevin McGann, Accelus President & CEO, has been named to the company's...
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
Conference Call and Webcast Scheduled for March 14, 2024 at 2:00 p.m. PT/5:00 p.m. ETSOUTH SAN FRANCISCO, Calif., March 05,...
Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal
Dr. Roizen to provide expertise on longevity and aging Research on aging involving Telomir’s lead product candidate focused on reversing age-related...
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and only FDA approved solution...
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
BELTSVILLE, Md., March 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
CORAL GABLES, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company...
Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
Dr. Jay Wohlgemuth, former Chief Medical & Scientific Officer of Quest Diagnostics and Dr. Ray Tabibiazar, a seasoned industry executive,...
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights
NXP800 preliminary data update expected this month from the Phase 1b study in platinum resistant, ARID1a mutated ovarian cancer, a...
Inspire Medical Systems, Inc. to Present at the KeyBanc Life Sciences & MedTech Investor Forum
MINNEAPOLIS, March 05, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on...
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused...
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on...
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
Patients with Alzheimer’s Disease show improvement in brainwaves following 4 weeks of XPro™ therapy. Boca Raton, Florida, March 05, 2024...
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
Clinical testing of LP-410 expected to commence in Q2 2024PITTSBURGH, March 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq:...